Legend Biotech (LEGN) Stock Forecast & Price Target

Legend Biotech is supported by a best-in-class CAR-T franchise in Carvykti, which posted Q2:26 global sales of $657M, including $472M in the U.S. and $185M ex-U.S., with collaboration profits of $326M and an improving commercial footprint as 2-4L patients represented about 70% of volume and outpatient use reached 60% of the mix. Its fundamental upside is reinforced by strong clinical differentiation and expanding access, since Carvykti’s durable efficacy in multiple myeloma is contrasted with competitive BCMA therapies by a materially cleaner outpatient-friendly safety profile for etentamig, while management also expects capacity constraints to be resolved and still sees a path toward sustained profitability. The outlook is further strengthened by an emerging in vivo pipeline, especially LB2501 and LB2505, where early proof-of-concept data, a planned U.S. IND in Q4:26, and a Chinese IIT in multiple myeloma suggest that Legend could diversify beyond Carvykti and extend its collaboration upside with JNJ.

Legend Biotech is viewed negatively because its economics remain highly concentrated in CARVYKTI and therefore vulnerable to competitive and execution risks, with newer BCMA therapies like AbbVie’s etentamig raising the efficacy bar in later-line multiple myeloma and potentially pressuring repeated-dose BCMA bispecifics before altering CARVYKTI’s commercial trajectory. The company also faces substantial commercialization risk from manufacturing and capacity constraints, since continued investment in production indicates demand visibility but broader access still depends on slot allocation at medical centers and physician selection, which can slow uptake even as over 70% of U.S. CARVYKTI volume now comes from 2L-4L and >40% use in 2L/3L provides some protection. In addition, the downside case explicitly hinges on CARTITUDE-5/6 failing to show statistically significant results, slower-than-anticipated adoption, or significant manufacturing bottlenecks, underscoring that the stock’s fundamental outlook is impaired by clinical, operational, and competitive uncertainty despite a favorable multiple myeloma market backdrop.